PRINCIPAL ENDPOINT To value valganciclovir efficacy in advance treatment of CMV in patients received allogenic transplant with a uniform treatment.

SECONDARY ENDPOINT To value valganciclovir security in advance treatment of CMV in in patients received allogenic transplant with a uniform treatment.

The security will be valued by the % of patients that:

Will have negative CMV Neutropenia <1000 neutrophils/mm3 or <500 neutrophils/mm3 in the first 35 days of treatment - follow-up Renal toxicity in the first 35 days of treatment - follow-up (defined by elevated creatinine >1mg/dL or twice the basal value) CMV illness during the treatment or in the next 2 months Blood Antigenemia / PCR positive in the next 2months of treatment

This dates Hill be compared with a patients control group treated with intravenous valganciclovir

Clinical trial with a drug in new conditions of use

Inclusion Criteria:

• Patients > 18 years old
• Any patients with allogenic TPH
• Following in post-TPH with antigenemia or PCR-CMV
• CMV in blood test detected by antigenemia or PCR before the day 180 post-TPH
• The beginning of treatment must be Duch early as possible. Maximum in the 72 hours from the antigenemia or PCR-CMV detection
• Be the first or second time of a CMV infection
• Sign the informed consent
• Pregnancy negative test in fertile age patients

Exclusion Criteria:

• Patients received auto or syngenic TPH
• Patients <50 kg weight
• Known allergy or hypersensibility patients to valganciclovir, ganciclovir or aciclovir
• Digestive intolerant: nauseous, vomit and or diarrhea that could difficult oral administration of valganciclovir
• Patients that presents CMV infection or that is being evaluated for suspected CMV
• Patients that have presented >2 CMV infection episode, before the current one
• Severe liver disease defined by bilirubin ≥ 10mg/dL
• Treated with: foscarnet, ganciclovir, cidofovir or another antiviral drug active to CMV, in the previous 30 days at the current episode
• Neutrophils < 500 /µL at the beginning of valganciclovir treatment. Patients with >500 PMN/µL and < 1000/µL must start a G-CSF treatment to get neutrophils value > 1000/µL
• Platelets < 25/mm3 even receiving transfusion
• Clearance Creatinine < 10mL/min or dialysed patients
• Pregnancy or lactant women
• Other contraindication detailed in the "filling card"
• Previous inclusión in this study at the treated group. Is allowed that a patient participate as a control case and after that receive valganciclovir treatment in after CMV episode